Arzerra (ofatumumab) is a prescription drug that’s used to treat chronic lymphocytic leukemia. The drug comes as a liquid solution for infusion by a healthcare professional. You’ll receive Arzerra on ...
Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) This is an ASCO Meeting Abstract from the 2004 ...
Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...
The FDA granted accelerated approval to lisocabtagene maraleucel (liso-cel, Breyanzi) for pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), drugmaker Bristol Myers ...
Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.
PURPOSE: Rituximab has been reported to have little activity in small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL) and to be associated with significant infusion-related toxicity.
This year’s most-read articles on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) explored treatment adherence patterns, patient symptom assessment, research on treatment ...
Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...
Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of cases, patients with CLL will develop lymphoma, a complication known as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results